KRAS G12C MUTANT SOLID TUMORS
Clinical trials for KRAS G12C MUTANT SOLID TUMORS explained in plain language.
Never miss a new study
Get alerted when new KRAS G12C MUTANT SOLID TUMORS trials appear
Sign up with your email to follow new studies for KRAS G12C MUTANT SOLID TUMORS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug targets 'Undruggable' cancer mutation in lung and colon tumors
Disease control OngoingThis study is testing a new drug called JDQ443, both alone and in combination with other treatments, for patients with advanced solid tumors that have a specific genetic change called KRAS G12C. The main goals are to find safe doses and see if the treatments can shrink tumors. It…
Matched conditions: KRAS G12C MUTANT SOLID TUMORS
Phase: PHASE1, PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Mar 23, 2026 15:17 UTC
-
New hope for tough cancers: experimental combo targets key mutation
Disease control OngoingThis study is testing new drug combinations for people with advanced solid tumors that have a specific genetic change called KRAS G12C. It focuses on patients with non-small cell lung cancer or colorectal cancer who have already tried standard treatments. The main goals are to fi…
Matched conditions: KRAS G12C MUTANT SOLID TUMORS
Phase: PHASE1, PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Mar 16, 2026 15:25 UTC